Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | KO-539 |
Synonyms | |
Therapy Description |
KO-539 is a small molecule inhibitor of MEN1 (menin)-KMT2A (MLL1) complex, which may lead to growth inhibition of KMT2A (MLL1)-positive tumor cells (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KO-539 | KO539|KO 539 | KO-539 is a small molecule inhibitor of MEN1 (menin)-KMT2A (MLL1) complex, which may lead to growth inhibition of KMT2A (MLL1)-positive tumor cells (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | predicted - sensitive | KO-539 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, KO-539 inhibited growth of KMT2A (MLL1)-rearranged acute myeloid leukemia cells in culture, and prolonged survival in cell-line xenograft models (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). | detail... |
DNMT3A wild-type FLT3 mut NPM1 mut | acute myeloid leukemia | predicted - sensitive | KO-539 | Preclinical - Pdx | Actionable | In a preclinical study, KO-539 treatment prevented disease progression in patient-derived xenograft (PDX) models of DNMT3A wild-type acute myeloid leukemia harboring mutations in NPM1 and FLT3 (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). | detail... |
DNMT3A mut FLT3 exon 14 ins NPM1 mut | acute myeloid leukemia | predicted - sensitive | KO-539 | Preclinical - Pdx | Actionable | In a preclinical study, KO-539 treatment resulted in clearance of leukemia cells in patient-derived xenograft (PDX) models of acute myeloid leukemia harboring mutations in NPM1, DNMT3, and FLT3 exon 14 (ITD) (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-A27). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04067336 | Phase I | KO-539 | First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 1 |